摘要
新型分子诊断药品Florbetapir F-18是目前惟一获美国食品药品管理局批准上市的用于PET成像脑组织中β-淀粉样斑块检测的放射性诊断药物,能协助临床阿尔茨海默病或其他认知减退疾病的诊断。本文简单综述Florbetapir18-F的药效学、药动学、安全性及临床效果等,以期指导临床应用。
As a novel molecular imaging agent,Florbetapir F-18 is the only radioactive dignostic agent approved by FDA for PET imaging of the brain to estimate β-amyloid plaque density.Florbetapir F-18 helps physicians to evaluate the patient with cognitive impairment for Alzheimer disease and other causes of cognitive decline.This article gives a brief review on pharmacology,safety and clinical application of Florbetapir F-18 to provide the information for clinical practice.
出处
《世界临床药物》
CAS
2013年第5期298-301,共4页
World Clinical Drug
